Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis

Kidney International

Volumn 70, Issue 3, 2006, Pages 515-522

  Huang, Y ^a   Border, W A ^a   Lawrence, D A ^b   Noble, N A ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Fibrosis Research Laboratory   (United States)

Author keywords

ECM degradation; Fibrosis; Kidney; PAI 1; Plasmin

Indexed keywords

ALPHA 2 ANTIPLASMIN; APROTININ; COLLAGEN TYPE 1; FIBRIN; MESSENGER RNA; PLASMIN; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANEXAMIC ACID; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EXTRACELLULAR MATRIX; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MESANGIUM CELL; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; ZYMOGRAPHY;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; CELLS, CULTURED; COLLAGEN TYPE I; EXTRACELLULAR MATRIX; FIBRINOLYSIN; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS; MACROPHAGES; MALE; MESANGIAL CELLS; MONOCYTES; MUTATION; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; TRANEXAMIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TRITIUM;

EID: 33746539889     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000353     Document Type: Article

References (30)

1. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657-1666.
2. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
3. Schnaper HW. Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol 1995; 9: 104-111.
4. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996; 148: 1345-1350.
5. Mignatti P. Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int 1995; 47: S-12-S-14.
6. Liotta LA, Goldfarb RH, Brundage R et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-4636.
7. Mochan E, Keler T. Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta 1984; 800: 312-315.
8. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990; 50: 5997-6001.
9. He CS, Wilhelm SM, Pentland AP et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-2636.
10. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 1990; 29: 5783-5789.
11. Ramos-DeSimone N, Hahn-Dantona E, Sipley J et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-13076.
12. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209-F220.
13. Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995; 47: 1039-1047.
14. Eitzman DT, McCoy RD, Zheng X et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-237.
15. Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995; 14: 2969-2977.
16. Stefansson S, Petitclerc E, Wong MK et al. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001; 276: 8135-8141.
17. Lawrence DA, Olson ST, Muhammad S et al. Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into beta-sheet A. J Biol Chem 2000; 275: 5839-5844.
18. Huang Y, Haraguchi M, Lawrence DA et al. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 2003; 112: 379-388.
19. Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981; 673: 75-85.
20. Moser TL, Enghild JJ, Pizzo SV, Stack MS. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem 1993; 268: 18917-18923.
21. Plow EF, Herren T, Redlitz A et al. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-945.
22. Hattori N, Degen JL, Sisson TH et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106: 1341-1350.
23. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-1580.
24. Haraguchi M, Border WA, Huang Y, Noble NA. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 2001; 59: 2146-2155.
25. Lawrence D, Strandberg L, Grundstrom T, Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989; 186: 523-533.
26. Laug WE, Weinblatt ME, Jones PA. Endothelial cells degrade extracellular matrix proteins produced in vitro. Thromb Haemost 1985; 54: 498-502.
27. Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003; 64: 844-856.
28. Bagchus WM, Hoedemaeker PJ, Rozing J, Bakker WW. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest 1986; 55: 680-687.
29. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990; 86: 453-462.
30. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 1994; 45: 916-927.